Key facts
- It has raised $314.7M; the latest was IPO in Mar 2026.
- Notable investors include HSG (Hong Kong), CICC Capital, Beijing State-owned Capital Operation and Management, 5Y Capital, Source Code Capital — 19 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for METis TechBio
- ·The full record, as it builds
Funding rounds
No funding rounds for METis TechBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About METis TechBio
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company offers software that helps pharmaceutical companies accelerate the movement of new drugs in the pipeline by optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- metistechbio.com/
- Ownership
- In IPO Registration
METis TechBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in METis TechBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on METis TechBio in its N-PORT filings yet. We sweep new filings monthly.